Treatment advances in myeloproliferative neoplasms: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

ABSTRACT

Great advances have been made in understanding the pathogenesis,diagnosis,risk stratification and treatment of classic bcr-abl-negative myeloproliferative neoplasms (MPN).This article reviews current situation in the treatment of these MPNs presented in the 56th American Society of Hematology (ASH) annual meeting.